Xention Limited

Xention Limited

Atrial fibrillation drug development

Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.

The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.

In 2013 Xention partnered it lead drug with French pharmaceutical company Servier and his since progressed this programme into 2 Phase IIa studies.

Contact Name
Dr. Tim Brears

Company Position
Chief Executive

Contact Address
Unit 5, Quern House
Mill Court
Hinton Way
Great Shelford
Cambridgeshire CB22 5LD
UK